Saturday 17 October 2026 Export JAGX’s income statement to Excel — free account

Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024. In the quarter to June 2026, revenue fell 58.9%, EPS grew 95.6%, free cash flow grew 13.8% and total debt fell 83.9%, each against the same quarter a year earlier.

3.53 1.06 −23.09%

Follow JAGX

Alert me

Market cap: $8.9M
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: 3/9
Altman Z: −18.88
Beneish M: −6.24
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 8.93

Revenue 27.82

Net Income (37.50)

Free Cash Flow (6.68)

Net Debt (4.86)

Current Ratio 0.69

Debt/Equity 0.35

P/E ratio 0.00

Fwd P/E (0.67)

P/S ratio 0.01

P/B ratio 0.04

Past 5Y EPS Growth —

This Y EPS Growth 99.51%

Next Y EPS Growth (125.00%)

Next Y revenue growth 77.74%

Next 5Y EPS Growth 87.27%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.24%

10-year low 10-year high

P/B against its own 10 years 0.30%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6	8	8	7
Receivables	2	2	2	0
Inventory	9	10	9	7
Other	—	—	—	—
	28	32	20	18

	2023	2024	2025	Q'26
Payables	5	5	9	5
ST’ Debt	—	—	—	—
Other	—	—	—	2
	14	20	41	25

Compound Annual Growth %

	10y	5y	3y
Sales	46.18%	4.17%	(1.26%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	20	1	—	—	—
’25	2	3	3	3	12
’24	2	3	3	4	12
’23	2	3	3	2	10
’22	3	3	3	3	12
’21	1	0	1	2	4
’20	1	3	3	3	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	9	(5)	—	—	—
’25	(7)	(6)	(5)	(5)	(24)
’24	(7)	(8)	(6)	(8)	(29)
’23	(10)	(9)	(7)	(7)	(33)
’22	(8)	(10)	(9)	(6)	(33)
’21	(7)	(10)	(9)	(9)	(35)
’20	(4)	(4)	(3)	(4)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	9	(5)	—	—	—
’25	(7)	(6)	(5)	(6)	(24)
’24	(7)	(8)	(6)	(8)	(30)
’23	(10)	(9)	(7)	(7)	(33)
’22	(8)	(13)	(9)	(7)	(35)
’21	(7)	(10)	(9)	(9)	(35)
’20	(4)	(4)	(3)	(4)	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(203.90)	(235.38)	—	—	—
’25	(8.75k)	(5.38k)	(3.29k)	5.54k	(12.04k)
’24	(47.37k)	(1.41k)	(13.76k)	(8.06k)	(68.51k)
’23	(2.43)	(331.58k)	(300.00k)	(576.80k)	(1.41m)
’22	(23.32)	(8.79)	(8.89)	4.10	(36.90)
’21	(0.28)	(0.31)	(0.27)	(1.23m)	(88.23)
’20	(0.52)	(0.39)	(0.59)	(1.13)	(2.62)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	113,488,592,896.00	19,534,921,728.00	1,426,359,424.00	92,491,872.00	32,779,688.00	59,062,500.00	4,784,062.50	114,975.00	11,077.50	481.43	Analyst estimates 2026–2028 Powerpack
	High	855,815,618,560.00	282,791,247,872.00	81,860,624,384.00	6,449,625,088.00	228,571,872.00	792,028,096.00	66,740,624.00	7,205,625.00	283,500.00	17,456.25
People
People	Employees	23	36	40	29	34	52	60	49	49	49
	Revenue/emp, $m	0.01	0.12	0.11	0.20	0.28	0.08	0.20	0.20	0.24	0.23
Income, $m
Income, $m	Revenue	0	4	4	6	9	4	12	10	12	12
	Gross margin, %	63.32	79.81	37.37	33.92	65.05	46.18	83.11	79.13	83.27	67.21
	EBT	(15)	(35)	(32)	(39)	(34)	(53)	(48)	(42)	(39)	(54)
	EBT margin, %	(10,412.58)	(805.97)	(727.93)	(667.17)	(360.25)	(1,213.38)	(404.78)	(429.27)	(335.79)	(469.09)
	Net income	(15)	(22)	(32)	(39)	(34)	(53)	(49)	(42)	(39)	(54)
	Depreciation	1	18	8	7	5	7	14	16	3	2
Per share, $
Per share, $	Revenue	0.01	1.51	21.06	1.16	0.73	7.27	9.12	0.00	19,481.67	2,616.14
	Earnings	(1.35)	(7.59)	(153.27)	(7.76)	(2.62)	(88.23)	(36.90)	(1,413,166.00)	(68,509.46)	(12,041.18)
	Cash flow	(1.32)	(3.39)	(108.40)	(4.12)	(1.19)	(58.65)	(25.24)	0.00	(48,973.33)	(5,383.18)
	Capex	(0.01)	0.00	(0.03)	0.00	0.00	(0.01)	(1.28)	0.00	(385.00)	(9.32)
	Free cash flow	(1.33)	(3.39)	(108.43)	(4.12)	(1.19)	(58.66)	(26.52)	0.00	(49,358.33)	(5,392.50)
	Book value	(0.22)	5.96	68.59	4.14	1.34	19.88	(1.03)	0.00	10,823.33	(4,247.27)
	Shares, m	11	3	0	5	13	1	1	0	0	0
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	9,661,624,906,836.67	18,282,754,417.67	134,870,293.78	122,027,886.88	198,201,062.85	8,447,885.81	570,133.93	0.00	0.68	0.19
	P/B	0.00	4,619,252,667.34	110,645,202.84	78,642,009.45	108,133,762.05	3,089,646.92	0.00	0.00	1.22	0.00
	EV/Sales	9,661,624,906,852.75	18,282,754,420.39	134,870,295.98	122,027,886.56	198,201,063.48	8,447,888.02	570,135.09	2.68	2.14	0.96
	EV/FCF	(94,167,884,082.39)	(8,030,226,334.99)	(26,195,467.41)	(34,436,622.60)	(121,695,582.65)	(1,047,049.25)	(189,543.01)	(0.72)	(0.80)	(0.45)
Cash, $m
Cash, $m	Operating cash flow	(14)	(10)	(23)	(20)	(15)	(35)	(33)	(33)	(29)	(24)
	Capex	0	—	0	—	0	0	(2)	0	0	0
	Free cash flow	(15)	(10)	(23)	(20)	(15)	(35)	(35)	(33)	(30)	(24)
Balance, $m
Balance, $m	Working capital	(2)	(12)	(19)	(6)	5	13	(8)	14	12	(20)
	Total debt	4	13	16	0	12	25	18	31	24	15
	Net debt	2	12	(3)	(3)	4	8	12	25	16	7
	Shareholders’ equity	(2)	17	14	21	17	12	(1)	5	6	(19)
Returns, %
Returns, %	ROA	(184.54)	(93.10)	(75.93)	(115.49)	(97.53)	(109.45)	(94.23)	(84.10)	(73.89)	(116.79)
	ROIC	0.00	(73.57)	(163.06)	(105.59)	(77.34)	(128.34)	(196.99)	(72.85)	(87.61)	0.00
	ROE	(1,515.12)	(296.74)	(283.92)	(623.62)	(295.44)	(362.04)	(904.14)	(2,332.67)	(675.83)	729.95

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BIVI BioVie Inc.	$9.6M	— (loss-making)	—	—	n/m	+26.50% (above 0%: growing)	0.00%	0.00%	Compare
LSTA Lisata Therapeutics, Inc.	$9.6M	— (loss-making)	— (loss-making)	−98.30% (below 0%: shrinking)	n/m	+33.04% (above 0%: growing)	100.00%	0.00%	Compare
VTGN VistaGen Therapeutics, Inc.	$9.5M	— (loss-making)	— (loss-making)	+504.92% (above 0%: growing)	n/m	+22.23% (above 0%: growing)	100.00%	(904.34%)	Compare
CMMB Chemomab Therapeutics Ltd. Sponsored ADR	$9.4M	— (loss-making)	—	—	n/m	+47.89% (above 0%: growing)	0.00%	0.00%	Compare
MTVA MetaVia Inc.	$9.0M	— (loss-making)	—	—	n/m	−22.42% (below 0%: shrinking)	—	0.00%	Compare
JAGX Jaguar Animal Health, Inc.	$8.9M	0.0×	— (loss-making)	−58.88% (below 0%: shrinking)	n/m	+13.83% (above 0%: growing)	15.84%	(620.16%)
NKGN NKGen Biotech, Inc.	$8.8M	— (loss-making)	—	—	n/m	+28.68% (above 0%: growing)	100.00%	0.00%	Compare
CSCIF COSCIENS Biopharma Inc.	$8.6M	1.0×	—	+30.04% (above 0%: growing)	n/m	+113.30% (above 0%: growing)	55.27%	13.43%	Compare
IMRN IMMURON	$8.3M	— (loss-making)	—	+757.00% (above 0%: growing)	+12.00% (above 0%: growing)	+42.55% (above 0%: growing)	72.16%	0.00%	Compare
Median of peers	$9.2M	—	—	+267.48%	—	+30.86%	72.16%	0.00%

All 614 Biotechnology stocks →